TISIDB

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol Cell membrane Peripheral membrane protein Midbody, Midbody ring Note=Translocates, as a preformed complex with EXOC3/SEC6 and EXOC4/SEC8, to the plasma membrane in response to insulin through the activation of ARHQ (By similarity). Colocalizes with CNTRL/centriolin at the midbody ring (PubMed:16213214).
Domain	PF03081 Exo70 exocyst complex subunit
Function	Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. In adipocytes, plays a crucial role in targeting SLC2A4 vesicle to the plasma membrane in response to insulin, perhaps directing the vesicle to the precise site of fusion (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006887 exocytosis GO:0006914 autophagy GO:0010506 regulation of autophagy GO:0016236 macroautophagy GO:0016241 regulation of macroautophagy GO:0030260 entry into host cell GO:0035635 entry of bacterium into host cell GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044409 entry into host GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:2000535 regulation of entry of bacterium into host cell
Molecular Function	-
Cellular Component	GO:0000145 exocyst GO:0005813 centrosome GO:0005938 cell cortex GO:0030426 growth cone GO:0030427 site of polarized growth GO:0032584 growth cone membrane GO:0034451 centriolar satellite GO:0044448 cell cortex part GO:0044450 microtubule organizing center part GO:0099023 tethring complex GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04910 Insulin signaling pathway
Reactome	R-HSA-5620920: Cargo trafficking to the periciliary membrane R-HSA-5617833: Cilium Assembly R-HSA-264876: Insulin processing R-HSA-199991: Membrane Trafficking R-HSA-392499: Metabolism of proteins R-HSA-1852241: Organelle biogenesis and maintenance R-HSA-2980736: Peptide hormone metabolism R-HSA-1445148: Translocation of GLUT4 to the plasma membrane R-HSA-5653656: Vesicle-mediated transport R-HSA-5620916: VxPx cargo-targeting to cilium

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04910 Insulin signaling pathway

Reactome

R-HSA-5620920: Cargo trafficking to the periciliary membrane
R-HSA-5617833: Cilium Assembly
R-HSA-264876: Insulin processing
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-2980736: Peptide hormone metabolism
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
R-HSA-5620916: VxPx cargo-targeting to cilium

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EXOC7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EXOC7 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.05; FDR: 0.02150	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EXOC7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.14	0.492
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.026	0.991
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.264	0.875
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.307	0.32
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.204	0.939
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.438	0.899
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.083	0.832
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.118	0.948
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.006	0.997
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.191	0.914
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.92	0.715
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.017	0.806

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EXOC7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	15.4	-15.4	0.482
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	16.7	-16.7	1

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EXOC7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EXOC7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EXOC7. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EXOC7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EXOC7 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EXOC7 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EXOC7
Name	exocyst complex component 7
Aliases	EXO70; KIAA1067; YJL085W; Exo70p; 2-5-3p; EX070; exocyst complex component Exo70
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EXOC7 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EXOC7